These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 24614671

  • 1. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC, Hecht EM.
    Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
    [Abstract] [Full Text] [Related]

  • 2. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 3. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 01; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 4. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 01; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 5. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.
    Ann Neurol; 2015 Mar 01; 77(3):447-57. PubMed ID: 25581547
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S, Weinstock-Guttman B.
    Expert Opin Biol Ther; 2014 Jan 01; 14(1):115-26. PubMed ID: 24289270
    [Abstract] [Full Text] [Related]

  • 7. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 01; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 8. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 9. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F, Newsome SD, Viscidi R.
    Mol Cell Probes; 2015 Feb 17; 29(1):54-62. PubMed ID: 25483260
    [Abstract] [Full Text] [Related]

  • 10. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ, Hogg JP.
    Curr Opin Neurol; 2013 Jun 17; 26(3):318-23. PubMed ID: 23493158
    [Abstract] [Full Text] [Related]

  • 11. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.
    Ann Neurol; 2014 Jan 17; 75(1):108-15. PubMed ID: 24242357
    [Abstract] [Full Text] [Related]

  • 12. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL, Chitnis T, Healy BC.
    Mult Scler; 2014 May 17; 20(6):757-60. PubMed ID: 24189572
    [Abstract] [Full Text] [Related]

  • 13. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 May 17; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 14. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 15. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
    Mazda ME, Brosch JR, Wiens AL, Bonnin JM, Kamer AP, Mattson DH, Snook RJ.
    Int J Neurosci; 2013 May 29; 123(5):353-7. PubMed ID: 23252596
    [Abstract] [Full Text] [Related]

  • 16. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 17. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.
    Ann Neurol; 2012 Nov 30; 72(5):779-87. PubMed ID: 23280794
    [Abstract] [Full Text] [Related]

  • 18. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
    Wattjes MP, Barkhof F.
    Curr Opin Neurol; 2014 Jun 30; 27(3):260-70. PubMed ID: 24739400
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D, Giovannoni G.
    Pract Neurol; 2012 Feb 30; 12(1):25-35. PubMed ID: 22258169
    [Abstract] [Full Text] [Related]

  • 20. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Feb 30; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.